Related Experiment Video

Updated: Jun 6, 2026

Detection of Human Leukocyte Antigen Biomarkers in Breast Cancer Utilizing Label-free Biosensor Technology
08:27

Detection of Human Leukocyte Antigen Biomarkers in Breast Cancer Utilizing Label-free Biosensor Technology

Published on: March 24, 2015

Autoantibodies to tumor-associated antigens in breast carcinoma

Ettie Piura1, Benjamin Piura

  • 1Department of Obstetrics and Gynecology, Sapir Medical Center, Sackler School of Medicine, University of Tel-Aviv, Kfar-Saba 44281, Israel.

Journal of Oncology
|November 30, 2010
PubMed

Insights

Autoantibodies (AAbs) targeting tumor-associated antigens (TAAs) show potential in breast cancer detection. Measuring AAbs against a panel of TAAs, rather than a single one, may improve diagnostic accuracy for breast carcinoma.

Area of Science:

  • Oncology
  • Immunology
  • Biochemistry

Background:

  • Autoantibodies (AAbs) against tumor-associated antigens (TAAs) are found in cancer patients' circulation.
  • Research is exploring the role of circulating AAbs to TAAs in breast carcinoma.
  • Numerous TAAs have been identified that elicit circulating AAbs in breast cancer patients.

Purpose of the Study:

  • To review current knowledge on circulating AAbs to TAAs in breast carcinoma.
  • To highlight the diagnostic potential of AAbs in breast cancer detection.

Main Methods:

  • Literature review of studies identifying circulating AAbs to TAAs in breast carcinoma.
  • Analysis of identified TAAs that elicit AAbs in breast cancer patients.
  • Evaluation of the diagnostic value of single TAA AAbs versus panels of TAA AAbs.

Main Results:

  • A comprehensive list of TAAs eliciting AAbs in breast carcinoma is presented, including p53, MUC-1, HSPs, HER2/neu, GIPC-1, c-myc, c-myb, NY-ESO-1, BRCA1, BRCA2, endostatin, lipophilin B, cyclins B1/D1, fibulin, IGFBP-2, TOPO2α, and cathepsin D.
  • Measuring AAbs to a single TAA has limited value for breast carcinoma screening and early diagnosis.
  • Assessing AAbs against a panel of TAAs shows promising potential for breast carcinoma diagnosis.

Conclusions:

  • Circulating AAbs to a panel of TAAs hold significant promise for the screening and early diagnosis of breast carcinoma.
  • Further research into multi-TAA AAb panels could lead to improved diagnostic tools for breast cancer.

More Related Videos

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer07:45

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Published on: May 18, 2020

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...